Clearing-factor lipase in adipose tissue. Studies with puromycin and actinomycin.
1. When adipose tissue from starved rats is incubated in a medium containing glucose, insulin, heparin and actinomycin (5mug./ml.) the total clearing-factor lipase activity of the system increases at least tenfold over a period of 9hr. In the absence of actinomycin, enzyme activity also increases, but to a lesser extent and for only about 3hr. Some enzyme activity appears in the incubation medium in both the presence and the absence of actinomycin. 2. When the glucose and insulin of the incubation medium are replaced by pyruvate and heparin is omitted, an increase in the total clearing-factor lipase activity in the presence of actinomycin still occurs, but only after a lag of several hours. When only heparin is omitted from the medium, the rise in enzyme activity begins immediately, but there is a shoulder in the time-course curve after a few hours. In the absence of heparin, little enzyme activity appears in the incubation medium. 3. The increases in enzyme activity in the presence of actinomycin are prevented if puromycin (0.5mg./ml.) is present in the incubation medium. 4. Catecholamines and corticotrophin inhibit the increase in enzyme activity caused by actinomycin. 5. The clearing-factor lipase activity of adipose tissue from fed animals declines with a half-life of between 1 and 1.5hr. when the tissue is incubated in the presence of puromycin. The clearing-factor lipase activity of adipose tissue from starved animals is stable under similar circumstances, as is the raised activity found after such tissue has been incubated in the presence of actinomycin. 6. Clearing-factor lipase extracted from adipose tissue of fed animals is less stable in solution than that extracted from the tissue of starved animals after this has been incubated in the presence of actinomycin.
D000273:Adipose Tissue / Q000201:enzymology*; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D003609:Dactinomycin / Q000494:pharmacology*; D004822:Epididymis / Q000201:enzymology; D004837:Epinephrine / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D011691:Puromycin / Q000494:pharmacology*; D011773:Pyruvates / Q000494:pharmacology; D051381:Rats; D013217:Starvation / Q000201:enzymology*; D013997:Time Factors
D007328:Insulin; D011773:Pyruvates; D003609:Dactinomycin; D011691:Puromycin; D000324:Adrenocorticotropic Hormone; D006493:Heparin; D008071:Lipoprotein Lipase; D005947:Glucose; D009638:Norepinephrine; D004837:Epinephrine